Professional Documents
Culture Documents
11 T Cells Reciprocally
Regulate Acute Graft versus Host Disease
By Defu Zeng,* David Lewis,‡ Sussan Dejbakhsh-Jones,*
Fengshuo Lan,* Marcos García-Ojeda,* Richard Sibley,§
and Samuel Strober*
From the *Department of Medicine, Division of Immunology and Rheumatology; the ‡Department of
Pediatrics; and the §Department of Pathology, Stanford University School of Medicine, Stanford,
California 94305
ity of bone marrow T cells, including the NK1.11 popula- IFN-g/IL-4 production correlated with the capacity to in-
tion, to produce these cytokines after in vitro stimulation duce severe GVHD.
with calcium ionophore and PMA for 48 h, a time point To determine whether the high capacity of NK1.11
at which cytokine levels were maximal (21). Depletion of bone marrow T cells to produce IL-4 was important for
NK1.11 T cells from the bone marrow CD41/CD81 T cell the negative regulation of GVHD by this cell population,
population resulted in an eightfold reduction of IL-4 pro- bone marrow CD41/CD81 T cells from wild-type and
duction (Table I) that was highly significant (P , 0.01, two- IL-42/2 mice of the C57BL/6 background were used to
tailed Student’s t test). In contrast, secretion of IFN-g was induce GVHD in the irradiated BALB/c hosts. The surface
similar in unfractionated versus NK1.1-depleted bone mar- phenotype and percentages of bone marrow a/b1 T cells,
row CD41/CD81 T cells. In comparison, sorted peripheral particularly the NK1.11 and CD42CD82 T cell subsets, were
blood CD41/CD81 T cells secreted high levels of IFN-g similar in IL-42/2 (Fig. 2, F–H) and wild-type mice (Fig. 2,
and a low level of IL-4 (Table I). Therefore, a high ratio of C–E), indicating that IL-4 is not required for NK1.11 T cell
1077 Zeng et al.
Table I. Cytokine Production by Bone Marrow (BM) and Peripheral Blood (PB) T Cells
pg/ml pg/ml
PB CD41/CD81 T (wt, n 5 6) 18 6 4 566 6 75 32
BM CD41/CD81 T (wt, n 5 6) 528 6 67 1,216 6 108 2.3
BM CD41/CD81 T NK1.12 (wt, n 5 6) 73 6 13 992 6 52 14
BM CD41/CD81 T (IL-42/2, n 5 6) 060 1,657 6 267 —
BM CD42/CD82 T (wt, n 5 6) 829 6 58 1,492 6 100 1.8
BM CD42/CD82 T (IL-42/2, n 5 4) 060 1,024 6 56 —
BM CD41/CD81 T (wt, anti-NK1.1, n 5 4) 281 6 19 1,419 6 28 5
BM CD42/CD82 T (wt, anti-NK1.1, n 5 4) 247 6 8 1,305 6 114 5.3
development. The percentage of CD41 and CD81 NK1.11 NK1.12 CD41/CD81 bone marrow T cells to the trans-
T cells in the IL-42/2 mice was also similar to that in the plant significantly increased the survival of the irradiated
wild type (data not shown). Whereas 2.00 3 105 of wild- hosts (P , 0.01, log rank test) as compared to the injection
type CD41/CD81 bone marrow T cells failed to induce le- of only NK1.12 CD41/CD81 bone marrow T cells and
thal GVHD (Fig. 3 A), the addition of 1.00 3 105 of these TCD bone marrow (Fig. 3 B). Only 10% of host mice died
bone marrow T cells from IL-42/2 mice to the transplant by day 60 in the group that received CD42CD82 T cells. In
induced lethal GVHD in 90% of irradiated BALB/c hosts contrast, the addition of 1.00 3 105 sorted CD42CD82
by day 11 (Fig. 3 A). Reduction of the dose of IL-42/2 bone marrow T cells from IL-42/2 mice resulted in re-
CD41/CD81 T cells to 5.0 and 2.5 3 104 resulted in the duced survival, and 80% of hosts died by day 12 posttrans-
reduction of lethal GVHD to 60 and 50%, respectively (Fig. plantation. Surviving hosts given CD42CD82 bone marrow
3 A). Examination of surviving hosts at day 40 again T cells from wild-type or IL-42/2 donors were killed on
showed histopathological evidence of GVHD of the large day 60. Interestingly, the large intestines and skin of hosts
intestine (data not shown). Purified CD41 and CD81 bone given IL-42/2 CD42CD82 T cells showed more severe
marrow T cells from IL-42/2 donors secreted no detectable histopathological lesions of GVHD compared not only to
IL-4, and high levels of IFN-g that were not significantly recipients of wild-type CD42CD82 T cells but also to
different than that of cells from wild-type C57BL/6 mice hosts that received only NK1.12 CD41/CD81 T cells with
(Table I). Taken together, these results indicate that the TCD bone marrow (Fig. 4, E–H). The sorted CD42CD82
NK1.11 subset of CD41/CD81 bone marrow T cells in- bone marrow T cells from the IL-42/2 donors secreted a
hibited the induction of GVHD by NK1.12 subset and that high level of IFN-g (mean 1,024 pg/ml) that was similar to
this inhibition was IL-4 dependent. the level secreted by CD42CD82 bone marrow T cells
We attempted to directly test the suppressive capacity of (Table I). This indicates that the secretion of IFN-g by
purified NK1.11 CD41/CD81 T cells on GVHD. How- NK1.11 T cells, when it is unopposed by IL-4 secretion,
ever, as immunofluorescent staining of bone marrow T cells exacerbates rather than inhibits GVHD.
with anti-NK1.1 mAb, a step required for cell purification
by positive selection, substantially reduced the capacity of
CD41/CD81 T cells to secrete IL-4 in vitro (Table I), this Discussion
approach was not pursued. As an alternative approach, we We directly compared the ability of sorted CD4 and
performed experiments in which purified CD42CD82 a/b1 CD8 T cells obtained from the peripheral blood or bone
T cells from the bone marrow, which are almost all NK1.11 marrow of C57BL/6 mice to induce acute GVHD in le-
(Fig. 2 D), were combined with NK1.12 CD41/CD81 thally irradiated BALB/c hosts coinjected with stringently
bone marrow T cells and transplanted with TCD bone TCD C57BL/6 marrow cells. The peripheral blood T cells
marrow. These purified bone marrow CD42CD82 a/b1 were at least 30-fold more potent than the marrow T cells
T cells secreted levels of IL-4 (mean 829 pg/ml) and IFN-g on a per-cell basis as judged by mortality of the hosts dur-
(mean 1,216 pg/ml) that lacked a statistically significant dif- ing a 100-d observation period. In fact, no significant mor-
ference (P . 0.1) from that of NK1.11-containing bone tality was induced by the sorted marrow T cells in the dose
marrow CD41/CD81 T cells (Table I). Addition of 1.00 3 range tested unless the NK1.11 T cells were removed or
105 CD42CD82 bone marrow T cells and 2.00 3 105 the sorted marrow T cells were obtained from IL-42/2 do-
We thank A. Mukhopadhyay, A. Van Vollenhoven, and P. Stepak-Biek for excellent technical assistance
and V. Cleaver for preparation of the manuscript.
This work was supported by National Institutes of Health grants R01 HL57443, R01 HL58250, R01
AI40093, and R01 AI26940. D. Zeng was the recipient of a postdoctoral fellowship award from Dendreon
Corporation, Mountain View, CA.
Address correspondence to Samuel Strober, Division of Immunology and Rheumatology, Stanford Univer-
sity School of Medicine, 300 Pasteur Dr., Rm. S105B, Stanford, CA 94305. Phone: 650-723-6500; Fax:
650-725-6104; E-mail: sstrober@stanford.edu
Received for publication 3 December 1998 and in revised form 8 February 1999.